Erratum to: Integrated gene networks in breast cancer development (Functional and Integrative Genomics (2010) 10, (11-19) DOI: 10.1007/s10142-010-0159-2);Integrated gene networks in breast cancer development

Functional and Integrative Genomics

Volumn 10, Issue 1, 2010, Pages 11-19

  Ratkaj, Ivana ^a   Stajduhar, Emil ^b   Vucinic, Srdan ^c   Spaventi, Sime ^d   Bosnjak, Hrvojka ^b   Pavelic, Kresimir ^a   Kraljevic Pavelic, Sandra ^a  

^a University of Rijeka   (Croatia)

^b SESTRE MILOSRDNICE UNIVERSITY HOSPITAL   (Croatia)

^c RUDER BO KOVI INSTITUTE   (Croatia)

^d CROATIAN ACADEMY OF SCIENCES AND ARTS   (Croatia)

Author keywords

Breast cancer; Cancer profile; Genomics; hGH; HOXA1; Pax5; Proteomics

Indexed keywords

BIOLOGICAL MARKER; ERLOTINIB; GROWTH HORMONE; PROTEIN P53; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR HOXA1; TRANSCRIPTION FACTOR PAX5; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; AUTOCRINE EFFECT; BREAST CANCER; BREAST CARCINOGENESIS; CANCER GENETICS; CANCER GROWTH; CANCER RESEARCH; EARLY DIAGNOSIS; GENE EXPRESSION; GENETIC POLYMORPHISM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LIQUID CHROMATOGRAPHY; MALIGNANT TRANSFORMATION; MASS SPECTROMETRY; MICROARRAY ANALYSIS; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEOMICS; REVIEW; SIGNAL TRANSDUCTION; TISSUE MICROARRAY;

EID: 77949425111     PISSN: 1438793X     EISSN: 14387948     Source Type: Journal    
DOI: 10.1007/s10142-010-0194-z     Document Type: Erratum

References (38)

1. Bagnato A, Rosano L (2008) The endothelin axis in cancer. Int J Biochem Cell Biol 40(8):1443-1451
2. Becker S, Cazares LH, Watson P, Lynch H, Semmes OJ, Drake RR, Laronga C (2004) Surfaced-enhanced laser desorption/ionization time-of-flight (SELDI-TOF) differentiation of serum protein profiles of BRCA-1 and sporadic breast cancer. Ann Surg Oncol 11(10):907-914
3. Bertucci F, Birnbaum D, Goncalves A (2006) Proteomics of breast cancer: principles and potential clinical applications. Mol Cell Proteomics 5(10):1772-1786
4. Biscardi JS, Ishizawar RC, Silva CM, Parsons SJ (2000) Tyrosine kinase signaling in breast cancer: epidermal growth factor receptor and c-Src interactions in breast cancer. Breast Cancer Res 2(3):203-210
5. Børresen AL, Andersen TI, Eyfjörd JE, Cornelis RS, Thorlacius S, Borg A, Johansson U, Theillet C, Scherneck S, Hartman S et al (1995) TP53 mutations and breast cancer prognosis: particularly poor survival rates for cases with mutations in the zinc-binding domains. Genes Chromosomes Cancer 14(1):71-75
6. Busslinger M, Klix N, Pfeffer P, Graninger PG, Kozmik Z (1996) Deregulation of PAX-5 by translocation of the Eμ enhancer of the IgH locus adjacent to two alternative PAX-5 promoters in a diffuse large cell lymphoma. Proc Natl Acad Sci 99:6129-6134
7. Ceakite L, Haug O, Myklebost O, Aldrin M, Ostenstad B, Holden M, Frigessi A, Hovig E, Sioud M (2004) Analysis of humoral immune response to immunoselected phage-displayed peptides by a microarray-based method. Proteomics 4(9):2572-2582
8. Champine PJ, Michaelson J, Weimer BC, Welch DR, DeWald DB (2007) Microarray analysis reveals potential mechanisms of BRMS1-mediated metastasis suppression. Clin Exp Metastasis 24(7):551-565
9. Cicek M, Samant RS, Kinter M, Welch DR, Casey G (2004) Identification of metastasis-associated proteins through protein analysis of metastatic MDA-MB 435 and metastasis-suppressed BRMS1 transfected-MDA-MB-435 cells. Clin Exp Metastasis 21(2):149-157
10. Fontana S, De Leo G, Sedic M, Kraljevic Pavelic S, Alessandro R (2006) Proteomics in antitumor research. DDT: technologies 3:441-449
11. Gebre-Medhin M, Kindblom LG, Wennbo H, Törnell J, Meis-Kindblom JM (2001) Growth hormone receptor is expressed in human breast cancer. Am J Pathol 158(4):1217-1222
12. Gong Y, Yan K, Lin F, Anderson K, Sotiriou C, Andre F, Holmes FA, Valero V, Booser D, Pippen JE Jr, Vukelja S, Gomez H, Mejia J, Barajas LJ, Hess KR, Sneige N, Hortobagyi GN, Pusztai L, Symmans WF (2007) Determination of oestrogen-receptor status and ERBB2 status of breast carcinoma: a gene-expression profiling study. Lancet Oncol 8(3):203-211
13. Hathout Y, Gehrmann ML, Chertov A, Fenselau C (2004) Proteomic phenotyping: metastatic and invasive breast cancer. Cancer Lett 210(2):245-253
14. Ho J, Kong JW, Choong LY, Loh MC, Toy W, Chong PK, Wong CH, Wong CY, Shah N, Lim YP (2009) Novel breast cancer metastasis-associated proteins. J Proteome Res 8(2):583-594
15. Holmes ML, Pridans C, Nutt SL (2008) The regulation of the B-cell gene expression programme by Pax5. Immunol Cell Biol 86(1):47-53
16. Hudelist G, Singer CF, Kubista E, Czerwenka K (2005) Use of high-throughput arrays for profiling differentially expressed proteins in normal and malignant tissues. Anticancer Drugs 16(7):683-689
17. Jessani N, Niessen S, Wei BQ, Nicolau M, Humphrey M, Ji Y, Han W, Noh DY, Yates JR 3rd, Jefery SS, Cravatt BF (2005) A streamlined plaarform for high-content functional proteomics of primary human specimens. Nat Methods 2(9):691-697
18. Jonkers J, Moolenaar WH (2009) Mammary tumorigenesis through LPA receptor signaling. Cancer Cell 15(6):457-459
19. Jung EJ, Moon HG, Cho BI, Jeong CY, Joo YT, Lee YJ, Hong SC, Choi SK, Ha WS, Kim JW, Lee CW, Lee JS, Park ST (2007) Galectin-1 expression in cancer-associated stromal cells correlates tumor invasiveness and tumor progression in breast cancer. Int J Cancer 120(11):2331-2338
20. Kairouz R, Daly RJ (2000) Tyrosine kinase signalling in breast cancer: modulation of tyrosine kinase signalling in human breast cancer through altered expression of signalling intermediates. Breast Cancer Res 2(3):197-202
21. Kim DH, Bae J, Lee JW, Kim SY, Kim YH, Bae JY, Yi JK, Yu MH, Noh DY, Lee C (2009) Proteomic analysis of breast cancer tissue reveals up regulation of actin remodeling proteins and its relevance to cancer invasiveness. Proteomics Clin 3(1):30-40
22. Kreunin P, Urquidi V, Lubman DM, Goodison S (2004) Identification of metastasis-associated proteins in a human tumor metastasis model using the mass-mapping technique. Proteomics 4(9):2754-2765
23. Lane PD (1992) Cancer. p53 guardian of the genome. Nature 358:15-16
24. Mohankumar KM, Xu XQ, Zhu T, Kannan N, Miller LD, Liu ET, Gluckman PD, Sukumar S, Emerald BS, Lobie PE (2007) HOXA1-stimulated oncogenicity is mediated by selective upregulation of components of the p44/42 MAP kinase pathway in human mammary carcinoma cells. Oncogene 26(27):3998-4008
25. Nielsen UB, Cardone MH, Sinskey AJ, MacBeath G, Sorger PK (2003) Profiling receptor tyrosine kinase activation by using Ab microarrays. Proc Natl Acad Sci U S A 100(16):9330-9335
26. Nimeus E, Malmstrom J, Johnsson A, Marko-Varga G, Ferno M (2006) Proteomic analysis identifies candidate proteins associated with distant recurrences in breast cancer after adjuvant chemotherapy. J Pharm Biomed Anal 43(3):1089-1093
27. Pawlik TM, Hawke DH, Liu Y, Krishnamurthy S, Fritsche H, Hunt KK, Kuerer HM (2005) Proteomic analysis of nipple aspirate fluid from women with early-stage breast cancer using isotopecoded affinity tags and tandem mass spectrometry reveals differential expression of vitamin D binding protein. BMC Cancer 6:68
28. Powell B, Soong R, Iacopetta B, Seshadri R, Smith DR (2000) Prognostic significance of mutations to different structural and functional regions of the p53 gene in breast cancer. Clin Cancer Res 6(2):443-451
29. Robson EJD, He SJ, Eccles MR (2006) A Panorama of PAX genes in cancer and development. Nat Rev Cancer 6(1):52-62
30. Saitoh S, Cunningham J, De Vries EM, McGovern RM, Schroeder JJ, Hartmann A, Blaszyk H, Wold LE, Schaid D, Sommer SS et al (1994) p53 gene mutations in breast cancers in midwestern US women: null as well as missense-type mutations are associated with poor prognosis. Oncogene 9(10):2869-2875
31. Sun B, Zhang S, Zhang D, Li Y, Zhao X, Luo Y, Guo Y (2008) Identification of metastasis-related proteins and their clinical relevance to triple-negative human breast cancer. Clin Cancer Res 14(21):7050-7059
32. Tennis M, Krishnan S, Bonner M, Ambrosone CB, Vena JE, Moysich K, Swede H, McCann S, Hall P, Shields PG, Freudenheim JL (2006) p53 Mutation analysis in breast tumors by a DNA microarray method. Cancer Epidemiol Biomarkers Prev 15(1):80-85
33. von Mering C, Jensen LJ, Kuhn M, Chaffron S, Doerks T, Krüger B, Snel B, Bork P (2007) STRING 7 - recent developments in the integration and prediction of protein interactions. Nucleic Acids Res 35(Database issue):D358-D362
34. Vouyovitch CM, Vidal L, Borges S, Raccurt M, Arnould C, Chiesa J, Lobie PE, Lachuer J, Mertani HC (2008) Proteomic analysis of autocrine/paracrine effects of human growth hormone in human mammary carcinoma cells. Adv Exp Med Biol 617:493-500
35. Waters MJ, Conway-Campbell BL (2004) The oncogenic potential of autocrine human growth hormone in breast cancer. PNAS 101(42):14992-14993 Yang SX, Simon RM, Tan AR, Nguyen D, Swain SM (2005) Gene expression patterns and profile changes pre- and post-erlotinib treatment in patients with metastatic breast cancer. Clin Cancer Res 11(17):6226-6232
36. Yang F, Foekens JA, Yu J, Sieuwerts AM, Timmermans M, Klijn JG, Atkins D, Wang Y, Jiang Y (2006) Laser microdissection and microarray analysis of breast tumors reveal ER-alpha related genes and pathways. Oncogene 25(9):1413-1419
37. Zhang D, Tai LK, Wong LL, Chiu LL, Sethi SK, Koay ES (2005) Proteomic study reveals that proteins involved in metabolic and detoxification pathways are highly expressed in HER-2/neupositive breast cancer. Mol Cell Proteomics 4(11):1686-1696
38. Zhu T, Starling-Emerald B, Zhang X, Lee KO, Gluckman PD, Hichem C, Mertani HC, Lobie PE (2005) Oncogenic transformation of human mammary epithelial cells by autocrine human growth hormone. Cancer res 65(1):317-324